Blog Post created by Daniela-3-11-2016 on Jun 26, 2018

Price of Pfizer's smoking-cessation drug Chantix doubles in just 5 years: report | FiercePharma


Pfizer’s smoking-cessation drug Chantix nudged closer to blockbuster status last year, bringing in $997 million in sales—up 18% from 2016. But some portion of that may have come from price hikes, judging from a new report released by GoodRx, an aggregator of pricing and discount information on prescription drugs.

The price of a 30-day supply of Chantix has more than doubled to $485 since 2013, according to GoodRx. Sure, a big proportion of patients do get help paying for the drug from their health plans, but that assistance may not be so generous: Many insurers have relegated the drug to tier 3 status on their formularies, putting patients on the hook for high out-of-pocket costs, GoodRx reports.

“Chantix’s soaring price, coupled with its poor coverage, does not bode well for the estimated 37.8 million Americans who are currently smoking,” wrote GoodRx researcher Tori Marsh in a blog post. “Moreover, tobacco use disproportionally affects low-income populations—those that may not be able to afford to pay for Chantix.” Marsh told FiercePharma that the pricing information came from a “representative sample of U.S. prescription fills,” based on full list prices from pharmacies.